Top

Published in:

01-08-2021 | Original Communication

CIDP associated with Sjögren’s syndrome

Authors: Tabea Seeliger, Stefan Gingele, Lena Bönig, Franz Felix Konen, Sonja Körner, Nils Prenzler, Thea Thiele, Diana Ernst, Torsten Witte, Martin Stangel, Thomas Skripuletz

Published in: Journal of Neurology | Issue 8/2021

Abstract

Background

This study addresses the challenging characterisation and differentiation of CIDP versus CIDP in association with Sjögren’s syndrome to facilitate the process in clinical routine.

Methods

Patients with both CIDP and Sjögren’s syndrome and CIDP without Sjögren’s syndrome were compared concerning relevant differences in clinical, laboratory and electrophysiological findings. 154 patients who fulfilled the diagnostic EFNS/PNS criteria for CIDP were included in the analysis. 54 of these patients additionally fulfilled the ACR/EULAR classification criteria for Sjögren’s syndrome.

Results

The frequency of female patients was higher in patients with CIDP and Sjögren’s syndrome (52%) versus CIDP patients without Sjögren’s syndrome (28%). Furthermore, the occurrence of cranial nerve impairment was significantly higher in patients with Sjögren’s syndrome (39% versus 14%). There were no significant group differences in the evaluation of initial symptoms, severity of disability judged by INCAT disability scale score, presence or distribution of sensory deficits, limb weakness and the presence of ataxia, pain or dysautonomia, CSF laboratory or electrophysiological findings.

Conclusions

In conclusion, our data indicate that cranial nerve impairment and female gender might represent red flags for an additional Sjögren’s syndrome in patients with CIDP. The patterns of clinical disabilities and electrophysiological findings due to peripheral nerve damage are similar in both CIDP entities.

Available only for authorised users

Sjögren H (1933) Zur kenntnis der keratoconjunctivitis sicca. Acta Ophthalmol 13:1–39CrossRef

Seror R, Ravaud P, Bowman SJ et al (2010) EULAR Sjögren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis 69:1103–1109. https://doi.org/10.1136/ard.2009.110619CrossRefPubMed

Ramos-Casals M, Brito-Zerón P, Seror R et al (2015) Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatol (Oxf) 54:2230–2238. https://doi.org/10.1093/rheumatology/kev200CrossRef

Jaskólska M, Chylińska M, Masiak A et al (2020) Neuro-Sjögren: uncommon or underestimated problem? Brain Behav. https://doi.org/10.1002/BRB3.1665CrossRefPubMedPubMedCentral

Thiele T, Seeliger T, Witte T et al (2020) Severe polyneuropathy in primary Sjögren’s syndrome: Sjögren’s syndrome should be considered in patients with motor neuropathy. Z Rheumatol 79:707–709CrossRef

Seeliger T, Prenzler NK, Gingele S et al (2019) Neuro-Sjögren: peripheral neuropathy with limb weakness in Sjögren’s Syndrome. Front Immunol 10:1600. https://doi.org/10.3389/fimmu.2019.01600CrossRefPubMedPubMedCentral

Perzyńska-Mazan J, Maślińska M, Gasik R (2020) Neurophysiological features of peripheral nervous system involvement and immunological profile of patients with primary Sjögren Syndrome. J Rheumatol. https://doi.org/10.3899/jrheum.181464 (jrheum.181464)CrossRefPubMed

Delalande S, de Seze J, Fauchais A-L et al (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Med (Baltim) 83:280–291CrossRef

Teixeira F, Moreira I, Silva AM et al (2013) Neurological involvement in primary Sjögren syndrome. Acta Reumatol Port 38:29–36PubMed

10.

Van den Bergh PYK, Hadden RDM, Bouche P et al (2010) European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European federation of neurological societies and the peripheral nerve society: first revision. Eur J Neurol 17:356–363. https://doi.org/10.1111/j.1468-1331.2009.02930.xCrossRefPubMed

11.

Shiboski CH, Shiboski SC, Seror R et al (2017) 2016 American college of rheumatology/European league against rheumatism classification criteria for primary Sjögren’s syndrome. Ann Rheum Dis 76:9–16. https://doi.org/10.1136/annrheumdis-2016-210571CrossRefPubMed

12.

Hughes R, Bensa S, Willison H et al (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50:195–201CrossRef

13.

Stålberg E, Falck B, Gilai A et al (1999) Standards for quantification of EMG and neurography. The international federation of clinical neurophysiology. Electroencephalogr Clin Neurophysiol Suppl 52:213–220PubMed

14.

Schwenkenbecher P, Chacko LP, Wurster U et al (2016) Intrathecal synthesis of anti-Hu antibodies distinguishes patients with paraneoplastic peripheral neuropathy and encephalitis. BMC Neurol 16:136. https://doi.org/10.1186/s12883-016-0657-5CrossRefPubMedPubMedCentral

15.

Seror R, Theander E, Brun JG et al (2015) Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 74:859–866. https://doi.org/10.1136/annrheumdis-2013-204615CrossRefPubMed

16.

Seeliger T, Bönig L, Witte T et al (2020) Hearing dysfunction in patients with Neuro-Sjögren: a cross-sectional study. Ann Transl Med 8:1069–1069. https://doi.org/10.21037/atm-20-1856CrossRefPubMedPubMedCentral

17.

Mori K, Iijima M, Koike H et al (2005) The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain 128:2518–2534. https://doi.org/10.1093/brain/awh605CrossRefPubMed

18.

Carvajal Alegria G, Guellec D, Mariette X et al (2016) Epidemiology of neurological manifestations in Sjögren’s syndrome: data from the French ASSESS Cohort. RMD open 2:e000179. https://doi.org/10.1136/rmdopen-2015-000179CrossRefPubMedPubMedCentral

19.

Phuljhele S, Pujari A, Obedulla H et al (2019) Atypical presentation of primary Sjögren’s syndrome as optic neuritis. Can J Ophthalmol 54:e30–e32CrossRef

20.

Pars K, Pul R, Schwenkenbecher P et al (2017) Cerebrospinal fluid findings in neurological diseases associated with Sjögren’s syndrome. Eur Neurol 77:91–102. https://doi.org/10.1159/000454765CrossRefPubMed

21.

Hughes RAC, Bouche P, Cornblath DR et al (2006) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European federation of neurological societies and the peripher. Eur J Neurol 13:326–332. https://doi.org/10.1111/j.1468-1331.2006.01278.xCrossRefPubMed

22.

Beeson PB (1994) Age and sex associations of 40 autoimmune diseases. Am J Med 96:457–462CrossRef

23.

Alamanos Y, Tsifetaki N, Voulgari PV et al (2006) Epidemiology of primary Sjögren’s syndrome in north-west Greece, 1982–2003. Rheumatology 45:187–191. https://doi.org/10.1093/rheumatology/kei107CrossRefPubMed

24.

Izmirly PM, Buyon JP, Wan I et al (2018) The incidence and prevalence of adult primary Sjögren’s syndrome in New York county. Arthritis Care Res (Hoboken). https://doi.org/10.1002/acr.23707CrossRef

25.

Lunn MP, Manji H, Choudhary PP et al (1999) Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 66:677–680CrossRef

26.

Chio A, Cocito D, Bottacchi E et al (2007) Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry 78:1349–1353. https://doi.org/10.1136/jnnp.2007.114868CrossRefPubMedPubMedCentral

27.

Laughlin RS, Dyck PJ, Melton LJ et al (2009) Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 73:39–45. https://doi.org/10.1212/WNL.0b013e3181aaea47CrossRefPubMedPubMedCentral

28.

Sivadasan A, Muthusamy K, Patel B et al (2017) Clinical spectrum, therapeutic outcomes, and prognostic predictors in Sjogren’s syndrome-associated neuropathy. Ann Indian Acad Neurol 20:278–283. https://doi.org/10.4103/aian.AIAN_116_17CrossRefPubMedPubMedCentral

29.

Rajabally YA, Attarian S, Delmont E (2020) Evolving immunologic perspectives in chronic inflammatory demyelinating polyneuropathy. J Inflamm Res 13:543–549CrossRef

Title: CIDP associated with Sjögren’s syndrome
Authors: Tabea Seeliger
Stefan Gingele
Lena Bönig
Franz Felix Konen
Sonja Körner
Nils Prenzler
Thea Thiele
Diana Ernst
Torsten Witte
Martin Stangel
Thomas Skripuletz
Publication date: 01-08-2021
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 8/2021
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-021-10459-z

2024 ASCO Annual Meeting

Springer Medicine

CIDP associated with Sjögren’s syndrome

Abstract

Background

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2021

Contribution of multi-modal imaging to our understanding of dystonia pathogenesis

The neurological sequelae of pandemics and epidemics

Evolution of caloric responses during and between the attacks of Meniere’s disease

Predictors and outcomes of ischemic stroke in reversible cerebral vasoconstriction syndrome

Neurological manifestations of patients infected with the SARS-CoV-2: a systematic review of the literature

Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study